Bluedorn Todd M 4

What Happened Todd M. Bluedorn, a director of Medline Inc., was granted a total of 15,732 restricted stock units (RSUs) in two awards reported on this filing: 10,345 RSUs on 2025-12-16 and 5,387 RSUs on 2026-06-11. Both grants were reported with an acquisition price of $0.00 (standard for equity compensation awards), so no purchase cost is shown. These are award/grant transactions (code A) rather than open-market purchases or sales.

Key Details

• Transaction dates and amounts:
  • 2025-12-16: 10,345 RSUs granted @ $0.00 (total $0) — footnote F1.
  • 2026-06-11: 5,387 RSUs granted @ $0.00 (total $0) — footnote F2.
• Total RSUs granted in this filing: 15,732 RSUs; reported acquisition value: $0.00.
• Vesting:
  • F1 (10,345 RSUs) vest on March 30, 2027.
  • F2 (5,387 RSUs) vest on the earlier of the first anniversary of grant or the next annual meeting of stockholders.
• Prior reporting: The 12/16/2025 RSU grant was previously disclosed on the reporting person's Form 3 filed 12/17/2025 (per F1). The 6/11/2026 grant is newly reported here.
• Filing timeliness: The June 11, 2026 grant was reported on the Form 4 filed 6/15/2026 (within typical reporting window); the December 16, 2025 grant had been previously reported on Form 3 the next day.

Context

• These entries are equity compensation awards (RSUs) granted to a director as part of compensation and are not purchases or sales in the open market. RSUs typically convert to shares when they vest; until then they are restricted.
• Because these are compensation grants (A), they reflect grant activity rather than an immediate trading signal. No tax withholding, sale, or exercise of options is reported here.